Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes

Table 5 Comparison of treatment-related adverse events between the two groups of patients, n (%)

Adverse reaction type	Control group (n = 80)		Experimental group (n = 80)		χ2	P value
	Any level	≥ 3 level	Any level	≥ 3 level
Gastrointestinal reaction	50 (62.50)	10 (12.50)	53 (66.25)	12 (15.00)	0.245	0.620
Myelosuppression	58 (72.50)	22 (27.50)	61 (76.25)	25 (31.25)	0.295	0.587
Neurotoxicity	49 (61.25)	6 (7.50)	52 (65.00)	8 (10.00)	0.242	0.623
Total ≥ level 3		38 (47.50)		45 (56.25)	1.227	0.268

It compares the incidence of treatment-related adverse events between the two groups using the χ² test. The results show no statistically significant differences in the incidence rates of gastrointestinal reactions, myelosuppression, neurotoxicity, or the total incidence of grade ≥ 3 adverse events between the control and experimental groups (all P > 0.05).